Role of Redox Iron Towards an Increase in Mortality Among Patients: a Systemic Review and Meta-analysis

Overview

Journal Blood Res

Publisher Springer Nature

Specialty Hematology

Date 2019 Jul 17

PMID 31309086

Authors

Sankalp Sharma

Affiliations

Soon will be listed here.

Abstract

An increase in biochemical concentrations of non-transferrin bound iron (NTBI) within the patients with an increase in serum iron concentration was evaluated with the following objectives: (a) Iron overloading diseases/conditions with free radicle form of 'iron containing' reactive oxygen species (ROS) and its imbalance mediated mortality, and (b) Intervention with iron containing drugs in context to increased redox iron concentration and treatment induced mortality. Literature search was done within Pubmed and cochrane review articles. The Redox iron levels are increased during dys-erythropoiesis and among transfusion recipient population and are responsive to iron-chelation therapy. Near expiry 'stored blood units' show a significant rise in the ROS level. Iron mediated ROS damage may be estimated by the serum antioxidant level, and show reduction in toxicity with high antioxidant, low pro-oxidant levels. Iron drug therapy causes a significant increase in NTBI and labile iron levels. Hospitalized patients on iron therapy however show a lower mortality rate. Serum ferritin is a mortality indicator among the high-dose iron therapy and transfusion dependent population. The cumulative difference of pre-chelation to post chelation ROS iron level was 0.97 (0.62; 1.32; N=261) among the transfusion dependent subjects and 2.89 (1.81-3.98; N=130) in the post iron therapy 'iron ROS' group. In conclusion, iron mediated mortality may not be mediated by redox iron among multi-transfused and iron overloaded patients.

References

Hirano K, Morinobu T, Kim H, Hiroi M, Ban R, Ogawa S . Blood transfusion increases radical promoting non-transferrin bound iron in preterm infants. Arch Dis Child Fetal Neonatal Ed. 2001; 84(3):F188-93. PMC: 1721242. DOI: 10.1136/fn.84.3.f188. View

Esposito B, Breuer W, Slotki I, Cabantchik Z . Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients. Eur J Clin Invest. 2002; 32 Suppl 1:42-9. DOI: 10.1046/j.1365-2362.2002.0320s1042.x. View

Esposito B, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, Cabantchik Z . Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood. 2003; 102(7):2670-7. DOI: 10.1182/blood-2003-03-0807. View

Agarwal R, Vasavada N, Sachs N, Chase S . Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int. 2004; 65(6):2279-89. DOI: 10.1111/j.1523-1755.2004.00648.x. View

Feldman H, Joffe M, Robinson B, Knauss J, Cizman B, Guo W . Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol. 2004; 15(6):1623-32. DOI: 10.1097/01.asn.0000128009.69594.be. View

Pootrakul P, Breuer W, Sametband M, Sirankapracha P, Hershko C, Cabantchik Z . Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassemia/HbE patients treated with an oral chelator. Blood. 2004; 104(5):1504-10. DOI: 10.1182/blood-2004-02-0630. View

Pai A, Boyd A, McQuade C, Harford A, Norenberg J, Zager P . Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis. Pharmacotherapy. 2007; 27(3):343-50. DOI: 10.1592/phco.27.3.343. View

Dresow B, Petersen D, Fischer R, Nielsen P . Non-transferrin-bound iron in plasma following administration of oral iron drugs. Biometals. 2007; 21(3):273-6. DOI: 10.1007/s10534-007-9116-5. View

Miura K, Taura K, Kodama Y, Schnabl B, Brenner D . Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. Hepatology. 2008; 48(5):1420-9. DOI: 10.1002/hep.22486. View

10.

Daar S, Pathare A, Nick H, Kriemler-Krahn U, Hmissi A, Habr D . Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia. Eur J Haematol. 2009; 82(6):454-7. PMC: 2730549. DOI: 10.1111/j.1600-0609.2008.01204.x. View

11.

Zanninelli G, Breuer W, Cabantchik Z . Daily labile plasma iron as an indicator of chelator activity in Thalassaemia major patients. Br J Haematol. 2009; 147(5):744-51. DOI: 10.1111/j.1365-2141.2009.07907.x. View

12.

Cappellini M, Porter J, El-Beshlawy A, Li C, Seymour J, Elalfy M . Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica. 2009; 95(4):557-66. PMC: 2857545. DOI: 10.3324/haematol.2009.014696. View

13.

Rangel E, Esposito B, Carneiro F, Mallet A, Matos A, Andreoli M . Labile plasma iron generation after intravenous iron is time-dependent and transitory in patients undergoing chronic hemodialysis. Ther Apher Dial. 2010; 14(2):186-92. DOI: 10.1111/j.1744-9987.2009.00786.x. View

14.

Stefansson B, Haraldsson B, Nilsson U . Acute oxidative stress following intravenous iron injection in patients on chronic hemodialysis: a comparison of iron-sucrose and iron-dextran. Nephron Clin Pract. 2011; 118(3):c249-56. DOI: 10.1159/000321645. View

15.

Ellervik C, Tybjaerg-Hansen A, Nordestgaard B . Total mortality by transferrin saturation levels: two general population studies and a metaanalysis. Clin Chem. 2011; 57(3):459-66. DOI: 10.1373/clinchem.2010.156802. View

16.

Porter J, Lin K, Beris P, Forni G, Taher A, Habr D . Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias. Eur J Haematol. 2011; 87(4):338-48. PMC: 3229702. DOI: 10.1111/j.1600-0609.2011.01660.x. View

17.

Ginzburg Y, Rivella S . β-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism. Blood. 2011; 118(16):4321-30. PMC: 3204905. DOI: 10.1182/blood-2011-03-283614. View

18.

Hod E, Brittenham G, Billote G, Francis R, Ginzburg Y, Hendrickson J . Transfusion of human volunteers with older, stored red blood cells produces extravascular hemolysis and circulating non-transferrin-bound iron. Blood. 2011; 118(25):6675-82. PMC: 3242722. DOI: 10.1182/blood-2011-08-371849. View

19.

Breuer W, Ghoti H, Shattat A, Goldfarb A, Koren A, Levin C . Non-transferrin bound iron in Thalassemia: differential detection of redox active forms in children and older patients. Am J Hematol. 2011; 87(1):55-61. DOI: 10.1002/ajh.22203. View

20.

Aydinok Y, Evans P, Manz C, Porter J . Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response. Haematologica. 2011; 97(6):835-41. PMC: 3366647. DOI: 10.3324/haematol.2011.056317. View